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Abstract
The mechanism of action of several antiepileptic drugs (AEDs) rests on their ability to modulate 
the activity of voltage-gated sodium currents that are responsible for fast action potential 
generation. Recent data indicate that lacosamide (a compound with analgesic and anticonvulsant 
effects in animal models) shares a similar mechanism. When compared with other AEDs, 
lacosamide has the unique ability to interact with sodium channel slow inactivation without 
affecting fast inactivation. This article reviews these findings and discusses their relevance within 
the context of neuronal activity seen during epileptiform discharges generated by limbic neuronal 
networks in the presence of chemical convulsants. These seizure-like events are characterized by 
sustained discharges of sodium-dependent action potentials supported by robust depolarizations, 
thus providing synchronization within neuronal networks. Generally, AEDs such as phenytoin, 
carbamazepine and lamotrigine block sodium channels when activated. In contrast, lacosamide 
facilitates slow inactivation of sodium channels both in terms of kinetics and voltage dependency. 
This effect may be relatively selective for repeatedly depolarized neurons, such as those 
participating in seizure activity in which the persistence of sodium currents is more pronounced 
and promotes neuronal excitation.
The clinical effectiveness of lacosamide has been demonstrated in randomized, double-blind, 
parallel-group, placebo-controlled, adjunctive-therapy trials in patients with refractory partial 
seizures. Further studies should determine whether the effects of lacosamide in animal models and 
in clinical settings are fully explained by its selective action on sodium current slow inactivation or 
whether other effects (e.g. interactions with the collapsin-response mediator protein-2) play a 
contributory role.
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Epilepsy is a neurological disorder characterized by neuronal hyperexcitability associated 
with recurrent episodes of excessive synchronized neuronal activity manifesting 
phenotypically as seizures and, at times, as interictal electroencephalographic discharges 
without overt clinical manifestations. Similar patterns of neuronal activity are seen in animal 
models of epilepsy or when brain slices are treated with chemical convulsants in vitro. 
Intracellular recordings obtained from areas of the limbic system in rodents have firmly 
established that both focal and generalized epileptic discharges are characterized by 
sustained firing of sodium-dependent action potentials that ride on network-driven 
depolarizations, mainly reflecting ligand-gated, glutamatergic currents[1–3] (figure 1). In 
view of the involvement of sodium-dependent action potentials in the generation and 
propagation of epileptiform discharges, it is not surprising that several antiepileptic drugs 
(AEDs) target sodium channels.
Although less vigorously than in the 1990s, research aimed at discovering new 
pharmacological treatments for epileptic disorders continues to provide anticonvulsants with 
novel or more selective mechanisms.[5–9] The main rationale for this search rests on the fact 
that, in spite of the introduction of a dozen second-generation AEDs in the last 20 years, 
approximately one-third of patients with epilepsy fail to achieve complete seizure control 
with existing treatments.[10,11] In addition, currently available AEDs produce a wide range 
of adverse effects, some of which can be life threatening.[11,12] Newer AEDs with more 
specific targets are needed to increase the chance of controlling drug-resistant epileptic 
disorders, as well as to reduce the risk of adverse effects.
AEDs are discovered by screening procedures in animal models that invariably include the 
maximal electroshock (MES) and the subcutaneous pentetrazol (pentylenetetrazol; PTZ) 
tests in rodents.[13,14] Compounds found to be active in either the MES or PTZ tests are then 
investigated in a broader range of other experimental models of seizures and epilepsy before 
undergoing assessment in clinical trials. Screening in standard seizure models is relatively 
unbiased with respect to mechanisms of action, and has allowed identification of AEDs 
acting on novel targets, such as gabapentin[15] and pregabalin,[16] although levetiracetam is 
an exception to this rule in that it is inactive in the classical MES and PTZ tests.[17] 
Discovery of novel targets has also provided hints to understand the patho-physiological 
basis of some types of epilepsy.
In parallel, progress in genetic investigations has revealed that some epileptic syndromes are 
associated with mutations in the structure of ionic channel subunits, highlighting the need to 
target specific channel dysfunctions. This also applies to the family of voltage-gated sodium 
channels, for which genetically determined alterations have been identified in various 
epileptic disorders such as generalized epilepsy with febrile seizures plus (GEFS+) and 
severe myoclonic epilepsy of infancy.[18,19] In these conditions, some mutations (but not all 
of them) impair the mechanisms responsible for inactivation of sodium channels, leading to 
neuronal over-excitation.[18,20] An increase in low-threshold persistent sodium current has 
been described in the entorhinal cortex of pilocarpine-treated rats during the chronic 
epileptic stage, suggesting that the structure of voltage-gated sodium channels may also be 
altered by repeated exposure to the seizures themselves.[21] Similar changes have been 
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described in a subset of subicular neurons isolated from resected tissue obtained from 
patients with drug-resistant temporal lobe epilepsy.[22]
Blockade of voltage-gated sodium channels is a primary mechanism of action for many 
AEDs commonly used to treat convulsive seizures.[23,24] Many of these drugs, which 
include carbamazepine, oxcarbazepine, phenytoin, lamotrigine, topiramate and felbamate, 
possess unrelated chemical structures, and some of them exhibit a clinical efficacy profile 
that extends beyond epilepsy, which has led to their effective use in the treatment of other 
disorders such as bipolar disorder, migraine and neuropathic pain.[25,26] Although additional 
mechanisms may contribute to these activities, blockade of sodium channels is also likely to 
contribute to therapeutic effects in non-epileptic disorders.[25] The way by which sodium 
channel-blocking AEDs modify the kinetics of voltage-gated sodium channels differs from 
one drug to another, and it is likely that such differences influence their clinical activity 
spectrum. However, for most AEDs acting on sodium channels, the main effects that have 
been documented include a reduction in peak amplitude of the current and an alteration in 
fast inactivation parameters (table I; see also Ragsdale and Avoli[23]).
Recently, the new AED lacosamide ([R]-2-acetamido-N-benzyl-3-methoxypropionamide; 
also known as SPM-927, harkoseride or ADD-234037) was found to exert anticonvulsant 
effects through a new, stereoselective mode of interaction with sodium channels. In fact, this 
compound, which belongs to a novel class of anticonvulsant agents collectively referred to 
as functionalized amino acids, acts primarily by interfering with the slowly inactivating 
component of voltage-gated sodium currents, without affecting the fast component that is 
targeted by traditional sodium channel blockers.[29,33]
In this article, we discuss lacosamide and its particular mode of action in relation to its 
experimental and clinical activity profile. In doing so, we first summarize some functional 
and molecular characteristics of voltage-gated sodium channels and discuss the actions of 
available AEDs on sodium currents. Second, we review the studies demonstrating the 
activity of lacosamide in experimental models of seizures, epilepsy and neuropathic pain, as 
well as the clinical studies supporting its use in the treatment of partial-onset seizures. Third, 
we briefly discuss potential relationships between the ability of lacosamide to control 
seizures and neuropathic pain and its specific sodium-dependent mechanism. The 
information reviewed in this article was derived from the author’s files and from a literature 
search (with the latest update on 10 February 2009) using the online database, PubMed, and 
the keywords ‘lacosamide’, ‘harkoseride’, ‘SPM 927’, ‘ADD 234037’, ‘sodium channels 
and epilepsy’ and ‘sodium channels and slow inactivation’.
1. Voltage-Gated Sodium Channels as Targets for Lacosamide and Other 
Antiepileptic Drugs
The voltage-gated sodium channel is composed of α subunits that surround a central pore, 
which is relatively selective for sodium ions. Four accessory β subunits, which are not 
involved in forming the channel pore, have been shown to modulate the biophysical 
properties of the channel. To date, nine isoforms of the main subunit, α1−9, have been 
described, with a rather conserved structure represented by four domains, each consisting of 
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six transmembrane segments and a re-entrant loop. In addition, some charged residues in the 
protein, responsible for the selectivity filter of the channel and for all the voltage-dependent 
mechanisms described below, are often well conserved.
Sodium channels occur physiologically in three different states (figure 2), and the transition 
among these states is voltage dependent. At membrane potentials close to the resting 
potential of the cell, sodium channels are mainly closed, and passage of ions across the 
membrane is not possible. When the membrane depolarizes, the channels switch to the open 
state through an ‘activation’ mechanism that develops within a few milliseconds.[34–36] The 
open state is the only conductive state of the channel, and sodium ions can pass through the 
channel by following their electrochemical gradient. The depolarizing stimulus (which can 
be applied through an amplifier during a voltage-clamp experiment or occurs as a result of a 
synaptic excitatory event in a physiological system) causes the opening of the channel.
However, the same depolarization induces conformational changes in other portions of the 
channel; thus, a portion of protein located on the intracellular side (the so-called ball and 
chain) is attracted towards the channel pore within a few tens of milliseconds from the 
delivery of the depolarizing stimulus and, by obstructing the pore, triggers the fast 
inactivation process. If the depolarizing stimulus lasts longer, up to seconds, a slow 
inactivation mechanism also takes place. This is mediated by a portion of the protein located 
on the extracellular side that is also displaced by the depolarization but with slower kinetics. 
The two inactivated states of the channel are both non-conducting, but they are biophysically 
different from the closed state.[35,36] In fact, to allow re-opening of the channel, the portions 
of the protein responsible for the fast and slow inactivation have to be removed from the 
pore and the only way for this to occur is through hyperpolarization of the membrane 
potential. These processes, known as recovery from fast and slow inactivation, respectively, 
occur with time constants that are of the same magnitude as those needed to induce the 
inactivation process, i.e. milliseconds for recovery from fast inactivation and up to seconds 
for recovery from slow inactivation. The hyperpolarizing stimulus also restores the 
activation gate to its closed condition, a mechanism known as deactivation.
Inactivation of sodium channels is of paramount importance for the actions of AEDs. Many 
AEDs, in fact, act on both fast and slow inactivation processes, whereas lacosamide may be 
unique in that it facilitates slow inactivation without altering the fast component (table I). In 
other words, lacosamide is highly selective for the slow inactivation phase of sodium 
currents. Binding experiments have demonstrated that la-cosamide displaces [3H]-
batrachotoxin bound to voltage-gated sodium channels, but does not compete with 
radioligands specific for amino-hydroxy-methyl-isoxazole propionic acid (AMPA), kainate, 
N-methyl-D-aspartate (NMDA), GABA, adenosine, muscarinic, histamine, dopamine, nor-
adrenaline (norepinephrine) and other receptors, and it does not alter type N, P, L and T 
calcium channels, the delayed rectifier or the IA potassium current at concentrations up to 
100 μmol/L.[29] In line with these findings, the passive membrane properties are not altered 
by lacosamide.
Patch-clamp experiments in the voltage-clamp configuration using mouse N1E-115 
neuroblastoma cells, described by Errington et al.,[33] have also revealed that lacosamide 
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decreases the amplitude of the sodium current at all membrane potentials tested, without 
affecting the potential at which 50% of the channels are activated (voltage of semi-
activation, V50Act).[33] Fast inactivation (figure 3a–c), as well as the recovery from fast 
inactivation, is not altered by lacosamide in these experiments. However, lacosamide 
facilitates the switch of sodium channels to the non-conducting slow-inactivated state (time 
constant for entry, τ = 4.79 s vs 11.95 s in controls),[33] and shifts the voltage of semi-
inactivation (V50Inact) for slow inactivation to more hyperpolarized potentials in a 
concentration-dependent manner (figure 3d). In contrast with observations made for sodium 
channels involved in pain (see section 4), no effect on the recovery from the slow 
inactivation has been observed in the study published by Errington et al.[33]
The effects of lacosamide were also characterized in voltage clamp experiments in which 
stimulation trains (30 test pulses, 20 ms to 0 mV from holding potential of −80 mV) were 
applied to mouse N1E-115 neuroblastoma cells. In this experiment, peak current amplitude 
measured at the 30th pulse was markedly reduced by carbamazepine, lamotrigine and 
phenytoin, but not by lacosamide.[33] In another set of experiments, lacosamide only reduced 
the number of current transients evoked with a slow depolarizing voltage ramp (from −70 
mV to +20 mV, 3 mV/s) in primary neocortical neurons obtained from Sprague-Dawley rats 
during embryonic days 16–18, whereas carbamazepine and phenytoin completely abolished 
them.[33] In the presence of a faster ramp (90 mV/s), spikes were almost insensitive to 
lacosamide, whereas sensitivity to carbamazepine and phenytoin, which act on fast 
inactivation, was fully retained.[33] In the experiments using the fast depolarizing ramp, the 
latency to the first spike was decreased by lacosamide, whereas it was increased by 
carbamaze-pine and phenytoin. In experiments in which 10 s sustained repetitive firing was 
evoked in current clamp, lacosamide did not affect the firing rate in the early phase of the 
burst, but attenuated it in the later stage. Conversely, carbamazepine, lamotrigine and 
phenytoin all produced a marked reduction in firing frequency within the first second of the 
burst.[33]
A relevant observation from the studies conducted by Errington et al.[33] is that the 
concentrations at which lacosamide was found to reduce sodium channel availability are 
comparable to those at which lacosamide inhibits ictal-like events in rodent brain slices 
(values for the concentration that produces a 50% effective response [EC50] of around 40 
μmol/L for clonic and 70 μmol/L for tonic seizures, see figure 3b in Lees et al.[37]). These 
concentrations are also of a similar order of magnitude to those found in the plasma of 
patients who received lacosamide in clinical trials (10–60 μmol/L).[38,39]
2. Lacosamide Effects in In Vitro Seizure Models
In a neuronal cellular monolayer system in vitro, perfusion with lacosamide 100 μmol/L 
markedly reduced the rate of occurrence of spontaneous inhibitory and excitatory 
postsynaptic currents.[29] Lacosamide also decreased, in a concentration-dependent manner, 
the frequency of spontaneous action potentials and the spikes-per-burst frequency induced 
by depolarizing current steps in cultured neocortical cells.[29] Interestingly, lacosamide 
reduced and eventually abolished the ictal-like activity induced by fampridine (4-amino-
pyridine) 100 μmol/L application in rat brain slices from the visual cortex. In this model, 
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lacosamide mainly affected the tonic phase of ictal events, so that the residual discharges 
included only a clonic-like component. In agreement with these findings, lacosamide has 
also been shown to reduce the population spike frequency of epileptiform events elicited by 
high-frequency stimulation.[37] These effects were stereoselective, as the S-stereoisomer 
SPM-6953 was devoid of activity.
3. Studies in In Vivo Models of Seizures and Epilepsy
The first experiments with functionalized amino acids were performed in the MES-induced 
seizure model and demonstrated that a variety of compounds within this class are effective in 
suppressing seizures with EC50 values comparable to the EC50 of phenobarbital (22 mg/kg, 
intraperitoneal [IP]).[40] Lacosamide stood out among other functionalized amino acids for 
its greater potency (EC50 of 8.3 mg/kg IP, 3.9 mg/kg orally),[40,41] and was selected for 
further development. In additional experiments, lacosamide was found to be effective against 
sound-induced seizures in the genetically susceptible Frings mouse.[42] Although 
lacosamide is inactive in the subcutaneous (SC) PTZ seizure model, it is effective in 
increasing seizure threshold in animals given continuous intravenous (IV) infusion of 
PTZ.[42] In the latter model, lacosamide effects have been analyzed in relation to the 
behavioural sequence of motor seizures, and the drug was found to significantly increase the 
threshold of the first twitch and of the clonus induced by IV PTZ. Lacosamide does not 
affect the threshold of clonic seizures induced by SC bicuculline and picrotoxin in mice, but 
it prevents NMDA-induced seizures and mortality.[42] In the 6 Hz model of refractory 
psychomotor seizures, lacosamide (20 mg/kg), injected IP 30 minutes before electrical 
stimulation, completely antagonized both seizure occurrence and the seizure-induced 
increase in glucose uptake, without suppressing normal brain metabolic activity.[42,43] In the 
amygdala and hippocampal kindling models of focal epilepsy, pre-treatment with 
lacosamide has been found to delay the acquisition of kindling and to reduce after-discharge 
duration.[42,44]
Lacosamide has been found to be effective in animal models of status epilepticus (SE). In 
the cobalt/homocysteine SE model, lacosamide effectively blocked generalized tonic-clonic 
seizures, although less potently than in the kindling model. This effect was potentiated by 
the concomitant administration of diazepam.[42] In the perforant path model of self-
sustained SE in rats, lacosamide also reduced cumulative seizure duration and SE-induced 
hippocampal damage.[38] The latter finding suggests that lacosamide may have 
neuroprotective activity, a possibility supported by evidence from other experimental 
models. A study conducted in the middle cerebral artery occlusion model of ischaemia in 
rats, in particular, found that lacosamide decreases infarct volume when administered 15 
minutes before occlusion and for 4 hours post-infusion.[45] Additionally, lacosamide has 
been found to inhibit, in a concentration-dependent manner, the glutamate- and oxygen-
glucose deprivation-induced apoptosis in organotypic rat hippocampal slice cultures.[45] 
However, lacosamide was ineffective in preventing brain damage or functional deficits in a 
rat model of traumatic brain injury.[45]
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4. Effects in Non-Epilepsy Models
Lacosamide has been found to possess analgesic effects in several animal models, including 
the rat model of spinal cord or trigeminal nerve injury,[46] tumour- and chemotherapy-
induced cancer pain,[47] muscle pain induced by tumour necrosis factor-α,[48] a rat model of 
osteoarthritis pain[49] and a rat model of painful diabetic neuropathy.[50] Lacosamide has 
also been found to reduce hyperalgesia when morphine fails to do so.[47]
The analgesic activity of lacosamide is likely to be mediated, at least in part, by the 
mechanisms responsible for its anticonvulsant effects, including facilitation of slow 
inactivation of voltage-gated sodium channels.[51] In line with this hypothesis, lacosamide 
has been tested on sodium channels NaV1.7 and NaV1.3 expressed in HEK293 cells, and on 
NaV1.8 in dorsal root ganglia neurons of adult Sprague-Dawley rats.[51] These types of 
sodium channels are known to be involved in human pain and hereditary painful 
neuropathies, pain following chronic inflammation and nerve injury, and inflammatory and 
neuropathic pain mechanisms, respectively. Lacosamide inhibited NaV1.7, NaV1.3 and 
NaV1.8 current amplitudes without affecting the voltage dependency of activation and fast 
inactivation, or recovery from fast inactivation. Channels in the inactivated state were more 
sensitive to lacosamide than channels in the resting state. Lacosamide shifted the voltage 
dependency for slow inactivation to more hyperpolarized potentials, and increased time to 
recovery from slow inactivation.[51]
5. Clinical Pharmacology
Following intake of single oral doses of up to 800 mg, lacosamide shows linear pharmaco-
kinetics.[52] Absorption is rapid, with peak serum concentrations being achieved within 4 
hours of administration, and oral bioavailability is virtually complete.[39,53] The 
bioavailability of lacosamide is not affected by concomitant intake of food.[54] With a twice-
daily dosage regimen, steady state serum concentrations are achieved after 3 days.[55] A 
parenteral formulation has been developed, which is intended for use as intravenous 
replacement therapy in patients temporarily unable to take oral medication. When infused 
intravenously over 30 or 60 minutes, the parenteral formulation produces serum 
concentration profiles comparable to those obtained after intake of equivalent oral 
doses.[39,53]
Lacosamide is negligibly (<15%) bound to plasma proteins, has a volume of distribution of 
0.5–0.8 L/kg and it is eliminated with a half-life of 12–16 hours.[45,52] Elimination occurs 
partly by urinary excretion in unchanged form (about 40% of an oral dose) and partly by 
metabolic biotransformation. The pharmacologically inactive O-demethylated derivative 
SPM-12809 is a primary metabolite and its recovery in urine accounts for about 30% of the 
administered dose.[55] The pharmacokinetics of lacosamide are influenced by renal function, 
and the serum concentrations of lacosamide and its main metabolite SPM-12809 increase 
with increasing degree of renal impairment. On average, serum lacosamide concentrations 
are increased by approximately 30% in patients with mild to moderate renal impairment and 
by 60% in patients with severe renal impairment (creatinine clearance <30 mL/min).[56]
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Population pharmacokinetic studies in patients with epilepsy receiving adjunctive therapy 
with lacosamide suggested that serum lacosamide concentrations are reduced by 
approximately 25% in the presence of concomitant treatment with enzyme-inducing AEDs 
such as carbamaze-pine, phenytoin and phenobarbital.[57] However, in previous 
pharmacokinetic studies, lacosamide pharmacokinetics were unaffected by concomitant 
treatment with carbamazepine 400 mg/day, or by valproic acid 600 mg/day.[52] In other 
clinical studies, lacosamide has not been found to affect the plasma concentrations of 
carbamazepine, carbamazepine-10,11-epoxide, phenytoin, valproic acid, lamotrigine, 
monohydroxy-carbazepine, topiramate, zonisamide, levetiracetam, gabapentin, metformin, 
digoxin, omeprazole, ethinylestradiol and levonorgestrel.[57–59]
6. Efficacy Data in Patients with Epilepsy
The efficacy of lacosamide has been investigated in three randomized, double-blind, 
parallel-group, placebo-controlled, adjunctive-therapy trials in adults with partial-onset 
seizures, with or without secondary generalization, unresponsive to other AEDs.[58,60,61] 
The three trials used a similar design, which included an 8-week baseline period, a titration 
period in which the target dose of lacosamide was gradually achieved in 100 mg/day 
increments each week, and a 12-week maintenance period. In all trials, the daily dose was 
given in two divided administrations (twice daily).
In the first trial, 418 patients were randomized to receive placebo or lacosamide dosages of 
200, 400 or 600 mg/day in addition to pre-existing medication with up to two AEDs.[58] A 
single back titration by 100 mg was allowed at the end of the 6-week titration period for 
those patients who could not tolerate the target dosage. The median percent reduction in 
seizure frequency from baseline to maintenance (primary endpoint) in the 200, 400 and 600 
mg/day groups was 26%, 39% and 40%, respectively, compared with 10% in the placebo 
group. The difference versus placebo was statistically significant (p < 0.01) for the 
intermediate and the highest dosage groups. A ≥50% reduction in seizure frequency during 
the maintenance period compared with baseline was reported in 21.9% of patients 
randomized to placebo, and in 32.7%, 41.1% and 38.1% of those randomized to 200 mg/day 
(not statistically significant), 400 mg/day (p = 0.004) and 600 mg/day (p= 0.014), 
respectively.
In the second trial, 485 patients receiving up to three AEDs were randomized to placebo or 
lacosamide dosages of 200 and 400 mg/day.[60] Patients assigned to the lacosamide 200 and 
400 mg/day groups had a median percent reduction in seizure frequency of 35.3% and 
36.4%, respectively, compared with 20.5% for placebo (p < 0.05 for both dosages). A ≥50% 
reduction in seizure frequency occurred in 25.8% of patients randomized to placebo and in 
35.0% and 40.5% of those randomized to 200 and 400 mg/day, respectively (p < 0.01 for the 
400 mg/day group).
The third trial, which has been reported only in summary form, compared placebo with 
lacosamide dosages of 400 or 600 mg/day in 405 patients receiving up to three concomitant 
AEDs.[61] A ≥50% reduction in seizure frequency was reported in 38.3% of patients 
receiving 400 mg/day and 41.2% of patients receiving 600 mg/day, compared with 18.3% of 
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patients in the placebo group (p < 0.001 for both dosages). Median percent reductions in 
seizure frequency were 37.3% for lacosamide 400 mg/day (p = 0.008) and 37.8% for 
lacosamide 600 mg/day (p = 0.006) compared with 20.8% for the placebo group.
A comparison of efficacy data in the three trials is reported in table II. A pooled analysis of 
data from the same trials showed that 2.7%, 3.3% and 4.8% of patients randomized to 
lacosamide 200, 400 and 600 mg/day, respectively, were completely free from seizures 
during the maintenance period, compared with a seizure-free rate of 0.9% for patients 
randomized to placebo.[9] Overall, the results of these studies indicate that lacosamide is 
effective in reducing the frequency of partial seizures in the 200–600 mg/day dosage range. 
However, the gain in efficacy at the 600 mg/day compared with the 400 mg/day dosage 
appears to be modest. In view of this result and because the highest dosage has a less 
favourable tolerability profile (see section 7), only the 200–400 mg/day dosage range has 
been approved by regulatory authorities in Europe and the US for use as adjunctive 
treatment of refractory partial-onset seizures in adults.
Long-term follow-up studies suggest that, in patients who responded favourably to 
lacosamide, response is maintained over time.[62] Lacosamide has not been tested in seizure 
types other than partial-onset seizures, and its potential value in the treatment of generalized 
epilepsies is unknown.
7. Tolerability Profile in Patients with Epilepsy
Based on observations made in adjunctive-therapy trials in patients with refractory partial-
onset seizures, the tolerability profile of lacosamide shows some similarities with that 
reported for traditional sodium channel-blocking agents such as carbamazepine and 
phenytoin. A pooled analysis of adverse effects reported in randomized, placebo-controlled 
epilepsy trials of lacosamide has been conducted recently.[63,64] The most common dose-
related adverse event was dizziness, which occurred in 53%, 30% and 16% of patients 
receiving dosages of 600, 400 and 200 mg/day, respectively, compared with 8% for patients 
randomized to placebo. Other dose-related adverse events were nausea, vomiting, abnormal 
coordination, tremor, nystagmus, diplopia, blurred vision and, possibly, fatigue, but for none 
of these events was the incidence at the highest dosage >17%. Remarkably, somnolence was 
very uncommon, and very few patients reported cognitive difficulties.[57,63]
Overall discontinuation rates due to adverse events during the treatment period were 8%, 
17% and 29% for lacosamide dosages of 200, 400 and 600 mg/day, compared with 5% for 
placebo.[9] CNS events, particularly dizziness, and gastrointestinal symptoms were the most 
common adverse events leading to discontinuation. The tolerability profile of the 
intravenous formulation appears to be similar to that of the oral preparation.[53]
Cardiac safety studies have shown that lacosamide does not affect corrected QT intervals. 
However, it causes a small dose-related prolongation of the PR interval.[64,65] The incidence 
of reported first-degree atrioventricular (AV) block in clinical trials in patients with epilepsy 
has been low (<1.0%), and there have been no reports of second- or higher degree AV block 
in patients treated with lacosamide in epilepsy studies.[64] However, caution is recommended 
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before using this drug in patients with pre-existing cardiac disease and in those taking class I 
anti-arrhythmics or drugs known to cause PR interval prolongation.[65]
8. Conclusions
The functionalized amino acid lacosamide has been shown to inhibit repetitive firing of 
neuronal cells by interfering with voltage-gated sodium currents, a mechanism shared by 
established AEDs such as carbamazepine, lamotrigine and phenytoin. However, at variance 
with these AEDs, lacosamide appears to possess a peculiar interaction with voltage-gated 
sodium channels. In fact, while carbamazepine, phenytoin and lamotrigine affect both fast 
and slow inactivation currents, lacosamide is devoid of effects on the fast inactivation 
component. In addition, the enhancement of slow inactivation of sodium channels caused by 
lacosamide is not use dependent, unlike the effect produced by classical sodium channel-
blocking AEDs. The precise molecular mechanisms by which lacosamide influences the 
function of sodium channels have not been defined, but they may involve an interaction with 
a novel binding site.[33]
The slow inactivation process, which is intrinsic to voltage-gated sodium channel 
functioning, is likely to play a major role during the paroxysmal depolarizing shifts 
associated with epileptic activity. Therefore, interference with this mechanism appears to be 
primarily responsible for the effectiveness of lacosamide in standard models of epilepsy, 
such as the MES test, and in less common paradigms such as the 6 Hz psychomotor model 
of treatment-resistant seizures.[38,43] These in vivo effects are consistent with observations 
made in vitro, demonstrating suppression of epileptic activity in systems such as fampridine-
induced tonic discharges and spike frequency in stimulated neuronal cell cultures or slices. 
In in vitro seizure models, the effects of lacosamide appear to be similar to those of other 
AEDs, such as carbamazepine. Lacosamide is also active in animal models of neuropathic 
pain, and an important role of sodium channel blockade in this activity is suggested by in 
vitro findings on sodium channels known to be involved in mediating neuropathic pain 
responses.
To date, the clinical effectiveness of lacosamide has been demonstrated in three randomized, 
double-blind, parallel-group, placebo-controlled, adjunctive-therapy trials in patients with 
refractory partial-onset seizures. Positive results have also been reported in trials conducted 
in patients with distal diabetic painful neuropathy.[66,67] Overall, these findings support the 
role of slow inactivation of sodium currents as a target for clinically significant drug effects 
both in epilepsy and neuropathic pain. However, it should be stressed that other actions may 
contribute to the efficacy of lacosamide in these conditions. In particular, recent findings 
suggest that lacosamide may also interfere functionally with collapsin-response mediator 
protein-2 (CMRP-2), a protein that has been implicated in the pathogenesis of both epilepsy 
and neuropathic pain.[38] However, these data should be interpreted with caution because, to 
date, they have only been reported in abstract form.[68] While the bulk of the evidence points 
to sodium channel blockade as the primary mechanism for the actions of lacosamide, further 
studies are required to define the potential contributory role of additional mechanisms.
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Fig. 1. 
Intracellular (top trace) and field (bottom trace) recordings from rat brain slices from the 
entorhinal cortex (a) and cingulate cortex (b) during application of fampridine (4-
aminopyridine) 50 μmol/L. Ictal network discharges (on the right side of the trace) 
correspond to high frequency sodium-dependent action potentials that ride on network-
driven depolarizations, while interictal events (on the left side of the trace) are associated 
with single action potentials or bursts of action potentials. Insets on the right are time 
expansions of the onset of ictal discharges and clearly show the very high frequency (up to 
200 Hz) discharges of action potentials (panel [a] modified from Lopantsev and Avoli,[4] 
with permission).
Curia et al. Page 15
CNS Drugs. Author manuscript; available in PMC 2016 May 24.
PM
C Canada A
uthor M
an
u
script
PM
C Canada A
uthor M
an
u
script
PM
C Canada A
uthor M
an
u
script
Fig. 2. 
Diagram illustrating the various states of the sodium channel. The sodium channel is in the 
closed state at resting potential (orange line in the current trace) and it switches to the open 
state after a depolarizing stimulus (activation, blue line in the current trace). The opposite 
mechanism (deactivation) occurs when the potential is repolarized. If the stimulus persists, 
the channel goes into the inactivated state through the mechanisms of fast and slow 
inactivation (pink line in the current trace). Repolarization of the membrane potential is also 
required to allow recovery from inactivation.
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Fig. 3. 
(a–c): Steady-state fast inactivation is modulated by carbamazepine (CBZ), phenytoin (PHT) 
and lamotrigine (LTG), but not by lacosamide (LCM) in mouse neuroblastoma cells. Sodium 
current tracings during the stimulus protocol (shown under CBZ traces) used to study 
steady-state fast inactivation are shown in (a). Note in (b) that the fast inactivation curve is 
not affected by lacosamide, while it is shifted to the left by carbamazepine, phenytoin and 
lamotrigine. Note also that the LTG curve is superimposed on that of PHT. Histograms 
shown in (c) summarize the half-inactivation potentials (V50; mean ± standard error of the 
mean [SEM]) and demonstrate that lacosamide does not alter fast inactivation, while the 
other drugs shift V50 potentials toward hyperpolarized values. (d) Slow inactivation is 
modulated by lacosamide. Note that lacosamide shifts the slow inactivation curve to the left 
in a concentration-dependent manner. Data are presented as means ± SEM. The stimulus 
protocol and the tracings used to create the slow inactivation curves are shown on the right 
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(modified from Errington et al.,[33] with permission). CONT = control; INa = sodium 
current; * p < 0.05, ** p < 0.001.
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